NCT06451536

Ga-68 FAPI PET Before Immunotherapy

Prognostic Significance of Ga-68 FAPI PET Before Immunotherapy in Pleural Mesothelioma

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Ankara University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PET/CT imaging, which allows in vivo evaluation of FAP expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.

Detailed description

Patients diagnosed with pleural mesothelioma and planned for immunotherapy will be included in the study. Patients will undergo Ga68 FAPI PET/CT imaging within 10 days before the start of immunotherapy treatment, and SUVmax, SUVmean, metabolic tumor volume and total Ga68 FAPI uptake parameters will be obtained from the tumors. Following this, the routine treatment and follow-up of the patients will be carried out by their clinicians. It will be evaluated whether there is a correlation between treatment response and initial Ga-68 FAPI PET findings.

Conditions

• Mesotheliomas Pleural

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Ga-68 FAPI PET/CT	imaging of FAP expression of tumor before immunotherapy

Timeline

• Start date: 2024-04-30
• Primary completion: 2025-04-30
• Completion: 2025-04-30
• First posted: 2024-06-11
• Last updated: 2024-06-11

Locations

1 site across 1 country: Turkey (Türkiye)